T h e ne w e ngl a nd jou r na l o f m e dicine C are of periviable infants remains a great challenge in neonatal and perinatal medicine. 1 Infants born between 22 and 24 weeks of gestation often die or survive with long-term neurodevelopmental impairment. [2] [3] [4] The approach to resuscitation and management at these early gestational ages varies substantially. 1, 5 Data reported during the past 5 years indicate that mortality has declined among extremely premature infants. [6] [7] [8] [9] Investigators at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) reported a decrease in mortality over the past two decades, with the greatest gains in survival seen among infants born at 23 and 24 weeks of gestation after 2008. 8, 9 Such studies raise questions about neurodevelopmental outcomes in surviving infants. NRN studies over previous periods have not shown significant improvement in neurodevelopmental outcomes over time among periviable infants, 2, 3 and there is concern that declining mortality in this population may lead to a greater number of infants surviving with neurodevelopmental impairment. 10, 11 The availability of data on both mortality and neurodevelopmental outcomes among survivors is important for families and clinicians making early care decisions for these high-risk infants. 1 The objective of our study was to evaluate changes over time in survival and neurodevelopmental outcomes among infants born at 22 to 24 weeks of gestation, as assessed at 18 to 22 months of corrected age (with corrected age defined as the age the infant would be if born at term). We hypothesized that in addition to the rate of survival, the rate of survival without neurodevelopmental impairment also increased from 2000 through 2011.
Me thods

Study Population and Data Collection
We included infants born at 22 weeks 0 days to 24 weeks 6 days of gestation between January 1, 2000, and December 31, 2011, who were enrolled in the generic database registry of the NICHD NRN. Data from the 11 academic tertiary care centers that participated in the NRN for the entire duration of the study period were included in the analysis. A total of 427 infants who were not born at the centers were excluded. Data for motherinfant dyads were collected prospectively by trained research personnel for all live births, which included infants who died in the delivery room. Gestational age was defined as completed weeks of gestation, as determined according to the best obstetrical estimate that was based on the last menstrual period, obstetrical factors, or prenatal ultrasonogram (or a combination thereof), orwhen obstetrical dating was unavailable -according to neonatal assessment that included the Ballard or Dubowitz examination. 12, 13 To assess whether there were changes in resuscitation practices over time, we evaluated the proportion of infants who did not receive active treatment after birth, which was defined by the use of surfactant, endotracheal intubation, ventilatory support (i.e., continuous positive airway pressure, bag-mask ventilation, or mechanical ventilation), chest compressions, epinephrine, or parenteral nutrition. 5 Small for gestational age was defined as birth weight below the 10th percentile on Olsen growth curves.
14 Severe intraventricular hemorrhage was defined as grade III to IV, according to the criteria of Papile et al. 15 The presence of sepsis was determined by a positive blood culture and was classified as early onset (≤72 hours) or late onset (>72 hours). Retinopathy of prematurity was considered to be severe if the infant received surgical treatment, intravitreal bevacizumab, or both. Necrotizing enterocolitis was defined as Bell's stage II to III, according to the modified Bell's classification (with scores ranging from I to III and higher scores indicating greater severity of disease). 16 Infants were considered to have bronchopulmonary dysplasia if they were receiving supplemental oxygen at 36 weeks of postmenstrual age (the infant's gestational age at birth plus the time elapsed since birth [chronological age]).
Study Oversight
The institutional review boards at each of the 11 centers approved the protocol, available with the full text of this article at NEJM.org. Nine centers required written informed consent for the follow-up protocol (2 centers granted a waiver), and 1 center required oral informed consent for the in-hospital protocol (10 centers granted a waiver). The third author, a statistician at the data coordinating center, had full access to the data and performed the analysis. All the authors vouch for the integrity, accuracy, and completeness of the data and analyses and for the fidelity of the study to the protocol. Bayley-II and Bayley-III motor scores and Bayley-III language scores were not included in the definition for neurodevelopmental impairment.
Given the potential discrepancy between Bayley-II and Bayley-III assessments, we chose neurosensory impairment as a secondary outcome to compare neurologic outcomes over time independent of Bayley scores. Neurosensory impairment was defined as moderate or severe cerebral palsy, Gross Motor Function Classification System level of at least 2, profound hearing loss, or profound visual impairment.
Statistical Analysis
We compared outcomes among infants in three birth-year epochs (2000) (2001) (2002) (2003) 8 and for consistency with previous NRN studies of neurodevelopmental outcomes in periviable infants over consecutive epochs. 2, 3 Demographics, perinatal characteristics, medical conditions, therapies, and outcomes were compared across epochs with the use of chi-square tests for categorical variables and median tests for continuous variables. Outcomes were stratified according to epoch for each of the participating centers. Multilevel generalized logit modeling was conducted to determine the effect of epoch on the three-level categorical outcome, with adjustment for gestational age, multiple gestation, maternal race, sex of the infant, and small-for-gestational-age status; birth center was included as a random effect. These covariates were selected to adjust for baseline factors that may influence outcomes. 22, 23 Variables related to care practices that may have changed over time, such as the use of antenatal glucocorticoids, were left out of the analysis so that the temporal effect would not be obscured. A similar modeling approach was used for the outcome of neurosensory impairment. Prespecified subgroup analyses were performed according to the gestational week in which the infants were born. Because changes in outcomes over time could reflect changes in resuscitation practices, we repeated the adjusted analyses with the sample limited to infants who received active treatment.
To further address the change from Bayley-II to Bayley-III, we performed a sensitivity analysis to evaluate changes in outcomes over the years since the implementation of Bayley-III. The analysis was restricted to infants born between 2006 and 2011. We used birth year, specified as a continuous variable, in place of epoch as the time variable in the model and adjusted for the same variables as in the regression model of the primary outcome.
All analyses were performed with the use of SAS software, version 9.3 (SAS Institute). Twosided P values of less than 0.05 were considered to indicate statistical significance. The primary outcome analysis was considered to be confirma-T h e ne w e ngl a nd jou r na l o f m e dicine tory, and all other reported analyses were deemed exploratory and hypothesis generating, with P values presented for descriptive purposes. Thus, no adjustments were made for multiple testing.
R esult s
Infant and Maternal Characteristics
A total of 4458 infants were born at 11 participating centers during the study period. The analysis cohort included 4274 infants (96%) for whom data on the primary outcome were available. The cohort comprised 749 infants (18%) born at 22 weeks, 1435 infants (34%) born at 23 weeks, and 2090 infants (49%) born at 24 weeks. Birth weight, gestational age, and infant sex distributions did not differ significantly across epochs, although the proportion of infants who were small for their gestational age increased significantly over time ( Table 1 ). The median maternal age increased over time, and the proportion of mothers with an education level less than high school decreased. The rates of multiple births, cesarean sections, and antenatal glucocorticoid use increased between epoch 1 and epoch 3, although the rate of antenatal antibiotic use decreased. Rates of active treatment did not change significantly across epochs. Active treatment was received by 22% of the infants (167 of 749) born at 22 weeks, by 71% (1015 of 1435) born at 23 weeks, and by 95% (1994 of 2090) born at 24 weeks.
The incidence of posthemorrhagic hydrocephalus with shunt placement, late-onset sepsis, and bronchopulmonary dysplasia decreased between epoch 1 and epoch 3 ( Table 1 ). The rate of postnatal glucocorticoid use also decreased between epoch 1 and epoch 3, although the rate of highfrequency ventilation increased. The percentages of infants with severe intraventricular hemorrhage, periventricular leukomalacia, early-onset sepsis, necrotizing enterocolitis, and ligation of a patent ductus arteriosus did not differ significantly across epochs. The incidence of severe retinopathy of prematurity was highest in epoch 2.
Outcomes
The percentage of infants who survived without neurodevelopmental impairment increased from 16% (217 of 1391) in epoch 1 to 20% (276 of 1348) in epoch 3 (P<0.001) ( Table 2 ). The rate of death was lowest in epoch 3 (64% [861 of 1348 infants died]). The proportions of infants who survived with neurodevelopmental impairment did not differ significantly across epochs. Among infants born at 22 weeks, there was no significant change in outcomes (survival without neurodevelopmental impairment, survival with neurodevelopmental impairment, and death) over time. Among infants born at 23 and 24 weeks, the rate of survival without neurodevelopmental impairment increased between epoch 1 and epoch 3, although the rate of survival with neurodevelopmental impairment did not differ significantly.
Among surviving infants, we found no significant difference in the incidence of neurodevelopmental impairment or neurosensory impairment across epochs ( Table 3 ). The incidence of profound visual impairment declined significantly to 2 of 484 infants (<1%) in epoch 3, but the rates of other individual components of neurodevelopmental impairment were similar over time. Survival and neurodevelopmental outcomes varied across centers (Fig. 1) .
Of the 4274 infants with data on the primary outcome, 4227 infants had complete data on all of the variables included in the generalized logit regression model (46 infants were excluded because of missing data on race and 1 infant was excluded because of missing data on small-forgestational-age status). After adjusting for baseline characteristics, we found that both the rate of survival with neurodevelopmental impairment versus death and the rate of survival without neurodevelopmental impairment versus death increased between epoch 1 and epoch 3 and between epoch 2 and epoch 3 ( Table 4 ). The increase in the rate of survival without neurodevelopmental impairment was not significantly greater than that of survival with neurodevelopmental impairment. Our findings were similar when we limited the analysis to infants who received active treatment.
After we excluded the Bayley score from our outcomes, we found that both the rate of survival with neurosensory impairment versus death and the rate of survival without neurosensory impairment versus death increased over time, but the increase in survival rate with neurosensory impairment did not differ significantly from the increase in survival rate without neurosensory impairment (Table 4) .
Among the infants born at 23 weeks, both the rate of survival without neurodevelopmental impairment versus death and the rate of survival without neurodevelopmental impairment versus survival with neurodevelopmental impairment in- * P values were determined using chi-square tests for categorical variables and median tests for continuous variables. † Race was determined by investigators on the basis of chart abstraction using categories specified in the study manual of operation (black, white, Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, or more than one race). ‡ Any receipt of antenatal glucocorticoids was defined as a full or partial course during the current pregnancy for the purpose of accelerating fetal maturity. A full course was defined as two doses of betamethasone (12 or 24 hours apart) or four doses of dexamethasone (≥6 hours apart). § Receipt of antenatal antibiotics was defined as receipt of any antibiotic preceding birth during the hospital admission in which delivery occurred. ¶ Active treatment was defined as the use of surfactant, endotracheal intubation, ventilatory support (i.e., continuous positive airway pressure, bag-mask ventilation, or mechanical ventilation), chest compressions, epinephrine, or parenteral nutrition. ‖ Data on medical conditions and therapies were available for infants surviving more than 12 hours and undergoing the applicable examination (e.g., sonogram for intraventricular hemorrhage). T Table 4) . Among the infants born at 24 weeks, both the rate of survival with neurodevelopmental impairment versus death and the rate of survival without neurodevelopmental impairment versus death increased over time, but the rates of increase did not differ significantly. There was no significant change in outcomes among the infants born at 22 weeks. However, the 95% confidence intervals for these estimates were wide, which reflects the small sample size in this gestational age group. In the sensitivity analyses to evaluate changes in outcomes among the infants eligible for the Bayley-III examination (i.e., infants who were born between 2006 and 2011), in which birth year was used in place of epoch in the regression model, we found that the rate of survival without neurodevelopmental impairment versus death increased from 2006 to 2011 (adjusted relative risk, 1.08 per 1-year increase; 95% confidence interval [CI], 1.04 to 1.13). The rate of survival with neurodevelopmental impairment versus death also increased (adjusted relative risk, 1.08; 95% CI, 1.03 to 1.13). The rate of survival without neurodevelopmental impairment versus survival with neurodevelopmental impairment did not change significantly over time (adjusted relative risk, 1.00; 95% CI, 0.96 to 1.05).
Discussion
Our study showed an increase in the rate of survival without neurodevelopmental impairment from 2000 through 2011 in a large cohort of periviable infants born at a consortium of U.S. academic tertiary care centers. A significant decline in mortality over the study period was accompanied by relative increases in both the rate of survival with neurodevelopmental impairment and the rate of survival without neurodevelopmental impairment. The increase in the rate of survival was not associated with a disproportionate increase in the rate of survival with neurodevelopmental impairment; rather, the rate of survival without neurodevelopmental impairment and the rate of survival with neurodevelopmental impairment increased similarly (adjusted relative risk, 1.27; 95% CI, 0.99 to 1.65). These findings are important for guiding counseling and decision making with respect to periviable birth. Prognosis continues to be guarded; in the most recent epoch, mortality was 64%, and 43% of surviving infants had neurodevelopmental impairment.
The improvements in survival and neurodevelopmental outcomes that we observed may reflect advances in obstetrical and neonatal care. We observed declines in the rates of postnatal glucocorticoid use, late-onset sepsis, posthemorrhagic hydrocephalus with shunt placement, and bronchopulmonary dysplasia over time, each of which has been independently associated with adverse neurodevelopmental outcomes. [24] [25] [26] [27] Proactive perinatal management has been associated with better outcomes among extremely premature infants, including an increased rate of survival and unchanged or reduced rates of disability among survivors. 5, 20, [28] [29] [30] In our study, the rates of cesarean delivery and antenatal glucocorticoid use increased over time. The improvement in outcomes was unlikely to be due to changes in the use of active treatment for infants, because the rates of active treatment were similar across epochs and the study findings did not change significantly when we restricted the analysis to infants who received active treatment. Changes in maternal characteristics may have contributed to the improvement in outcomes, because maternal age and level of education increased over time.
Previous studies of survival and neurodevelopmental outcomes among extremely premature infants have shown mixed results, with reports of increased, 10,11 unchanged, 2,3,31 or decreased rates of neurodevelopmental impairment over time. 32, 33 Many of these studies involved primarily more mature infants, and it is unclear whether the results can be extrapolated to the periviable population. Comparing neurodevelopmental outcomes across studies in this population would be complicated by sparse data and differences in sample selection, criteria used to define impairment, and age at follow-up. Studies from the United Kingdom, Sweden, and Japan, published in 2012 and 2013, showed rates of neurodevelopmental impairment of 34% (46 of 136 infants), 41% (56 of 138), and 47% (130 of 279), respectively, among surviving infants born at 22 to 24 weeks, as evaluated at 2.5 to 3 years of corrected age, as compared with a rate of 46% (627 of 1370) in our study. 20, 31, 34 Among infants born at 24 weeks, rates of neurodevelopmental impairment were higher in our study (44%) than in these three studies (30 to 37%). It is unclear how much of Survival and Neurodevelopment among Periviable Infants † P values were determined using chi-square tests. ‡ Included are 4274 infants who had data available on the primary outcome. § Among the 27 surviving infants born at 22 weeks, the median (interquartile range) gestational age was 22 weeks 5 days (22 weeks 4 days to 22 weeks 6 days) and birth weight was 570 g (510 to 620).
T h e ne w e ngl a nd jou r na l o f m e dicine this variation is due to differences in sample ascertainment, study design, infant characteristics, or care practices. We found variation in outcomes by center; this observation is consistent with the findings from other studies published in 2015 and 2004 that assessed extremely premature infants. 5, 22 In the subgroup analysis performed according to the gestational week in which the infants were born, we found that the rate of survival without neurodevelopmental impairment increased over time among infants born at 23 weeks and 24 weeks. However, only 1% of infants born at 22 weeks survived without neurodevelopmental impairment in each epoch. Among the 167 infants born at 22 weeks who received active treatment after birth, 9 (5%) survived without neurodevelopmental impairment.
The best measures of neurodevelopmental outcomes in premature infants continue to be debated. Our definition of neurodevelopmental impairment included measures of motor function, sensory impairment, and cognitive delay, which is consistent with the definition used in other studies. Clinicians and families should note that there is likely to be substantial variation in the longterm functioning of children classified as having neurodevelopmental impairment in early childhood. Although early neurodevelopmental assessment is important for the timely identification of children at risk for long-term neurologic impairment or developmental delay, its capacity to predict later functioning is limited. [35] [36] [37] Many children will catch up to their peers by school age, whereas other children will have persistent impairment. Conversely, some children without signs of neurodevelopmental impairment in early childhood will have impairments that manifest at school age. 37, 38 Bayley-II Mental Developmental Index and Bayley-III Cognitive Composite scores have been shown to correlate with later cognitive outcomes but account for only a minority of the variance in later cognitive functioning. 35, 36, 39 Reported rates of impairment at school age among children who were born extremely premature are generally lower than those reported in early childhood, but studies have been limited by small sample sizes and heterogeneous results. 35, 37, 40 Additional research is needed to better understand long-term outcomes among periviable infants.
Our analysis was complicated by the transition from Bayley-II to Bayley-III during the study period. Studies involving extremely premature infants have shown that Bayley-III Cognitive Composite scores are, on average, 10 to 11 points Shown are the rates of death, survival with neurodevelopmental impairment, and survival without neurodevelopmental impairment at the 11 centers that were included in the analysis. The rates were adjusted for gestational age at birth, multiple gestation, sex, race, and small-for-gestational-age status. Because of rounding, percentages may not total 100. higher than the Bayley-II Mental Developmental Index scores. 17, 18 To address this limitation, we defined cognitive impairment using a conservative Bayley-III Cognitive Composite score lower than 85, which is one standard deviation below the mean score of 100. Johnson et al. 21 * Comparisons were adjusted for gestational age (defined as completed weeks of gestation), multiple gestation, sex, race, small-for-gestational-age status, and birth center (random effect). Gestational age was not included in 22-, 23-, and 24-week subgroup analyses. † Data on survival and neurodevelopmental outcomes were available for 4227 infants (46 infants were excluded because of missing data on race, and 1 infant was excluded because of missing data on small-for-gestational-age status). ‡ Data on survival and neurodevelopmental outcomes were available for 737 infants. § Data on survival and neurodevelopmental outcomes were available for 1417 infants. ¶ Data on survival and neurodevelopmental outcomes were available for 2073 infants. ‖ Data on survival and neurodevelopmental outcomes were available for 3158 infants. scores. Finally, when we evaluated changes in outcomes in the years since the implementation of Bayley-III, the results were consistent.
Our study has additional limitations. The data represent a select group of infants born in a subset of academic centers and may not be generalizable to other populations. Furthermore, we did not correct for multiple testing, which increases the probability that some of the significant differences that we observed in our secondary outcomes analyses may have occurred by chance. There is a small chance that the changes in outcomes over time reflect random variation alone.
In conclusion, our study showed a small but significant increase in the rate of survival without neurodevelopmental impairment at 18 to 22 months of corrected age among periviable infants. Despite improvements over time, the incidence of death, neurodevelopmental impairment, and other adverse outcomes remains high in this population.
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